Price T Rowe Associates Inc Uro Gen Pharma Ltd. Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
A detailed history of Price T Rowe Associates Inc transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 393,984 shares of URGN stock, worth $4.15 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
393,984
Previous 12,839
2968.65%
Holding current value
$4.15 Million
Previous $164,000
2459.15%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding URGN
# of Institutions
138Shares Held
39.1MCall Options Held
9.8KPut Options Held
49.2K-
Rtw Investments, LP New York, NY3.83MShares$40.4 Million0.67% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA2.93MShares$30.9 Million0.06% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$24.3 Million0.15% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$23.1 Million0.0% of portfolio
-
Toronto Dominion Bank Toronto, Ontario, A61.75MShares$18.4 Million0.03% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $240M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...